Being able to detect early on whether a cancer therapy is working proffers obvious benefits for therapy-outcomes whilst influencing the course of treatment and improving the quality of life for … Continue Reading Novel ‘reporter’ nanoparticle reveals cancer treatment effectiveness in real-time.
Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment.
Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment. Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events. The study highlights gaps in how the long-term safety of drugs intended for chronic use in children is assessed as part of the FDA approval process.
Thoughts health innovators?